LENZ Therapeutics, Inc. announced the FDA approval of VIZZ (aceclidine ophthalmic solution) 1.44% prescription eye drops for the treatment of presbyopia in adults, according to a news release . Commercial samples are expected to be available in the United States as early as October 2025, with full market availability anticipated by mid-fourth quarter 2025.

Presbyopia is characterized by the loss of near vision due to aging. It impacts nearly all individuals over the age of 45 and is caused by the gradual hardening of the eye’s crystalline lens. This hardening makes it more difficult for the lens to focus on objects up close. It is typically self-diagnosed, and treatments include bifocal glasses or multifocal contact lenses. On average, adults over 50 lose 1.5 lines of near vision every

See Full Page